Literature DB >> 33282368

Charlson comorbidity index as a predictor of short-term outcomes after pulmonary resection.

Weipeng Shao1, Zhenrong Zhang2, Jun Zhang1, Hongxiang Feng2, Chaoyang Liang2, Deruo Liu1,2.   

Abstract

BACKGROUND: The objective of this retrospective study is to evaluate the impact of the CCI on short-term outcomes in pulmonary resection.
METHODS: We retrospectively analyzed 1,309 patients who underwent pulmonary surgery consecutively in our hospital.
RESULTS: All patients were divided into complication group and non-complication group. CCI (P=0.012), blood loss (P=0.015) and type of surgery (P<0.001) were an independent risk factors for complications in multivariate analysis. Assuming a threshold of 3 for defining poor outcomes for pulmonary resection, the sensitivity and specificity were 87.9% and 44.2%, respectively. The area under the curve for CCI was 0.711 (P<0.001). There were 918 (70.1%) patients in the CCI ≤3 group and 391 (29.9%) patients in the CCI ≤3 group. The rate of poor outcome was 3.3% in the CCI ≤3 group, and 9.2% in the CCI >3 group (P<0.001).
CONCLUSIONS: The main finding of the present study was that CCI >3 was associated with a poor short-term outcome. For patients with CCI >3, it was suggested that the experienced surgical team should perform pulmonary resection in the shortest time and preserving the lung function as much as possible. 2020 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Charlson comorbidity index (CCI); Pulmonary resection; complications; short-term outcome

Year:  2020        PMID: 33282368      PMCID: PMC7711382          DOI: 10.21037/jtd-20-2264

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


Introduction

Lung cancer is the leading cause of cancer death worldwide, accounting, for approximately 1.4 million deaths annually (1). The most effective treatment for early-stage lung cancer is surgical resection. However, only about 20% to 30% of patients are potential candidates for surgical resection because of the stage at which the disease is diagnosed or because of comorbid conditions (2). Comorbidity has been associated with overall and disease-specific outcomes in various cancers. Compared with patients with many other types of cancer, patients with lung cancer are more likely to harbor substantial comorbidity because of their advanced age at diagnosis and a strong association with cigarette smoking (3). All these comorbidities can have deleterious effects on the diagnostic procedures and, moreover, on the treatment possibilities and thus must be carefully explored. The Charlson comorbidity index (CCI) have been used to assess the comorbidity risk associated with several conditions. CCI is closely related to postoperative complications (4). The objective of this retrospective study is to evaluate the impact of the CCI on short-term outcomes after pulmonary resection, to determine the cutoff point of CCI with guiding significance for prognosis. We present the following article in accordance with the STARD reporting checklist (available at http://dx.doi.org/10.21037/jtd-20-2264).

Methods

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the institutional ethics board of China-Japan Friendship Hospital (No. 2018-13-K08) and individual consent for this retrospective analysis was waived.

Data collection

We retrospectively analyzed 1,309 patients who underwent pulmonary resection in China-Japan Friendship Hospital between January 2010 and January 2018. Perioperative data were collected for all patients, including age, sex, smoking history, American Society of Anesthesiologists (ASA) classification, CCI, surgical procedure, anesthesia time, operation time/one-lung ventilation time, blood loss, histology, complications (air leakage more than 1 week, pleural effusion needs re-thoracentesis, pulmonary infection (fever and culture positive), atrial fibrillation, re-thoracotomy, postoperative blood transfusion, pulmonary embolism, pneumothorax, chylothorax (whether somatostatin therapy is effective), atelectasis and/or sputum retention requiring bronchoscopy, wound sepsis and bronchopleural fistula), poor outcomes, 30-day mortality, and postoperative stay. However, since not all of these complications were irreversible or untreatable, not all of them would necessarily have precluded surgery if predicted in advance. We defined postoperative death or respiratory failure as poor outcomes. Poor outcomes were used to identify patients who should ideally be identified as high-risk patients before surgery.

CCI scoring

Comorbidity was defined as the presence of one or more additional conditions existing simultaneously, independently or not (with or without a causal effect) with a disease that was considered primary. In the CCI the patient’s age was allocated to one of the age groups, each considered to be of different risk. introduces the Charlson comorbidity index and the prevalence of comorbid conditions. The index score was further calculated the CCI calculator (5,6).
Table 1

Charlson comorbidity index and prevalence of comorbid conditions

Charlson index itemPointsNo. of patients%
Coronary artery disease1443.4
Peripheral vascular disease1161.2
Cerebrovascular disease1141.1
Chronic obstructive pulmonary disease114210.8
Connective tissue disease150.4
Liver disease1251.9
Diabetes mellitus1957.3
Chronic kidney disease270.5
Leukemia230.2
Malignant lymphoma210.08
Solid tumor2927

Statistical analysis

Categoric variables were expressed as percentages and evaluated with Chi square or Fisher’s exact test. Continuous data were presented as mean ± SD and were compared using the two-sample Student t test. Receiver-operating characteristic (ROC) curves were plotted to assess the predictive value of CCI for poor outcomes. All P-values were reported by 2-sided analyses, and the statistical significance level was set at less than 0.05. Statistical analysis was performed with SPSS 24.0 software (SPSS, Inc., Chicago, IL, USA).

Results

From January 2010 to January 2018, 1,309 patients underwent pulmonary resection. Demographic, clinical characteristics and operation procedures were presented in . In brief, the type of surgery performed consisted of wedge resection in 344 (33.1%) patients, segmentectomy in 38 (3.0%) patients, lobectomy in 831 (63.5%) patients, and bilobectomy in 96 (7.3%) patients. Nine hundred and six patients received the resection by video-assisted thoracoscopic surgery (VATS), the postoperative complication rate was 17.0%, 73 patients received the resection by video-assisted minithoracotomy (VAMT), the postoperative complication rate was 26.0%, 122 patients received the resection by thoracotomy, the postoperative complication rate was 27.7%. Nine hundred seventy-one (74.2%) patients were histologically diagnosed as malignant tumors, the rest 338 (25.8%) were histologically diagnosed as benign tumors. The postoperative pathology of all patients was shown in . Adenocarcinoma (AC), squamous cell carcinoma (SCC) and metastatic tumor were the top three in the malignant tumors. Tuberculosis (TB), hamartoma and inflammatory pseudotumor were the top three in the benign tumors. The proportion of each age group was shown in . There are 438 patients (33.5%) in the 51–60 age group and 425 patients (32.5%) in the 61–70 age group. Only 17 (1.2%) patients were in the age group of 81 years or older.
Table 2

Patient characteristics

CharacteristicsComplication groupNon-complication groupP
Age (years)60.76±17.0658.42±12.020.004
FEV1%pred74.92±11.1976.93±8.350.007
Anesthesia time (min)284.93±87.71247.75±106.540
Operation time (min)230.06±86.33192.45±92.570
Blood loss (mL)283.61±319.94180.08±231.540
Discharge (d)16.90±11.718.96±4.320
Sex0
   Male182573
   Female79475
Smoking history0.075
   Yes113391
   No148657
Surgery0
   Wedge37307
   Segmentectomy434
   Lobectomy177654
   Bilobectomy4353
Operative method0
   VATS154752
   VAMT73208
   Thoracotomy3488
Blood transfusion0
   Yes3468
   No227980
ASA classification0.127
   I/II221924
   III/IV40124
Pathology0.001
   Malignant214757
   Benign47291
Poor outcome0
   Yes2541
   No2361007
30-day death0
   Yes81
   No2531047
CCI0.005
   01174
   115117
   271270
   363297
   467190
   52571
   6624
   735

VATS, video-assisted thoracoscopic surgery; VAMT, video-assisted minithoracotomy; ASA, American Society of Anesthesiologists; FEV1%pred, predicted of forced expiratory volume in 1 s; CCI, Charlson comorbidity index.

Table 3

Distribution of pathological type

TypesNo. of patients%
AC70153.55
SCC24218.49
TB1037.87
Hamartoma423.21
Metastatic tumor382.90
Inflammatory pseudotumor352.67
Bronchiectasia342.60
SCLC312.37
Mycosis181.38
Pulmonary sequestration141.07
Sarcomatoid carcinoma120.92
Sclerosing hemangioma110.84
LCC100.76
Fibroma70.53
Bronchocyst50.38
Carcinoid40.31
Hemangioma20.15
Total1,309100

AC, adenocarcinoma; SCC, squamous cell carcinoma; TB, tuberculosis; SCLC, small cell lung cancer; LCC, large cell carcinoma.

Table 4

Distribution of age among patients undergoing surgery

Age, yearNo. of patients%
≤40947.2
41–5015611.9
51–6043833.5
61–7042532.5
71–8017913.7
≥81171.2
VATS, video-assisted thoracoscopic surgery; VAMT, video-assisted minithoracotomy; ASA, American Society of Anesthesiologists; FEV1%pred, predicted of forced expiratory volume in 1 s; CCI, Charlson comorbidity index. AC, adenocarcinoma; SCC, squamous cell carcinoma; TB, tuberculosis; SCLC, small cell lung cancer; LCC, large cell carcinoma. According to the occurrence of postoperative complications, they were divided into two groups. There were 261 (19.9%) patients in the complication group and 1,048 (80.1%) patients in the non-complication group. The mean age of the two groups was 60.76±17.06 and 58.42±12.02 years, respectively. In the complication group, the mean time of extubation and discharge was 12.21±10.97 days and 16.90±11.71 days. In the non-complication group, the mean time of extubation and discharge was 5.70±3.40 days (P<0.001) and 8.96±4.32 days (P<0.001). Univariate analysis identified that age (P<0.001), anesthesia time (P<0.001), operation time (P<0.001), sex (P<0.001), type of surgery (P<0.001), operative method (P=0.001), blood loss (P<0.001), intraoperative blood transfusion (P<0.001), CCI (P=0.005) were candidate risk factors for postoperative complications (). CCI (P=0.012), blood loss (P=0.015) and surgery (P<0.001) were an independent risk factors for complications in multivariate analysis (). The general rate of poor outcome was 5.0%, in the complication group and non-complication group, the rates were 9.6% and 3.9%, respectively. Nine patients died within 30 days after operation, 8 (3.1%) in the complication group and 1 (0.1%) in the non-complication group.
Table 5

Multivariate analysis to identify predictors of complications

CharacteristicsOR95% CIP
CCI0.7930.663–0.9500.012
Blood loss0.9990.999–1.0000.015
Surgery0.6550.530–0.8100

CCI, Charlson comorbidity index; OR, odds ratio; CI, confidence interval.

CCI, Charlson comorbidity index; OR, odds ratio; CI, confidence interval. The number and proportion of complications are shown in . The more common complications were air leakage (7.5%) and atrial fibrillation (6.6%). The rare complications were bronchopleural fistula (0.3%) and pulmonary embolism (0.2%). Solid tumors, cardiorespiratory diseases, diabetes accounted for a large proportion of comorbidity. Of the 1,309 patients, 85 (6.5%) patients had a CCI of 0, 132 (10.1%) patients had a CCI of 1, 341 (26.1%) patients had a CCI of 2, 360 (27.5%) patients had a CCI of 3, 257 (19.6%) patients had a CCI of 4, 96 (7.3%) patients had a CCI of 5, 30 (2.3%) patients had a CCI of 6, 30 (0.6%) patients had a CCI of 7. To find out the relationship between poor outcomes and CCI, and whether there was a bound value with predictive value. Receiver-operating characteristic (ROC) curves were plotted in order to assess the predictive value of CCI score results for poor outcomes. Positive and negative predictive values were calculated for selected thresholds and using study estimates of the prevalence of poor outcome. shows the ROC curves. The diagonal line indicates an area under the curve of 0.5, equivalent to the measurement having no predictive value. The area under the curve for CCI was 0.711 (95% CI: 0.651–0.771, P<0.001). Assuming a threshold of 3 for defining poor outcomes for pulmonary resection, the sensitivity and specificity were 87.9% and 44.2%, respectively.
Table 6

Incidence of postoperative complications

ComplicationsNo. of patients (n=261)%
Air leak (lasting >7 d)987.5
Atrial fibrillation876.6
Chylothorax231.8
Pneumonia352.7
Re-thoracotomy80.6
Postoperative blood transfusion151.1
Pulmonary embolism20.2
Pleural effusion503.8
Pneumothorax131
Atelectasis and/or sputum retention requiring bronchoscopy110.8
Wound sepsis120.9
Bronchopleural fistula40.3

One patient may have two or more complications.

Figure 1

Receiver-operating characteristic curve. ROC, receiver-operating characteristic; CCI, Charlson comorbidity index.

One patient may have two or more complications. Receiver-operating characteristic curve. ROC, receiver-operating characteristic; CCI, Charlson comorbidity index. All patients were grouped according to their CCI score and classified into CCI ≤3 group and CCI >3 group. As shown by , there were 918 (70.1%) patients in the CCI ≤3 group and 391 (29.9%) patients in the CCI >3 group. The mean age of the two groups was 54.49±10.60 and 69.23±7.46 years, respectively. Compared with the group with CCI >3, the operation time (P=0.053) and anesthesia time (P=0.058) of the group with CCI ≤3 were shorter, the intraoperative blood loss(P=0.368) was less, the extubation time (P=0.171) and discharge time (0.067) after operation were shorter, although there was no significant difference. Most patients (87.5%) have an American Society of Anesthesiologists (ASA) classification of I/II, 91.6% in the CCI ≤3 group, and 77.7% in the CCI >3 group (P<0.001). The incidence of postoperative complications was 17.4% in CCI ≤3 group and 25.8% in CCI >3 group (P<0.001). The 30-day postoperative mortality was 0.7% in all patients, 0.5% in the CCI ≤3 group, and 1.0% in the CCI >3 group (P=0.338). The rate of poor outcome was 3.3% in the CCI ≤3 group and 9.2% in the CCI >3 group (P<0.001). In the CCI ≤3 group, the VATS proportion was 67.0%; in the CCI >3 group, the VATS proportion was 74.4%.
Table 7

Demographic and clinical characteristics among patients by CCI

CharacteristicsCCI (≤3)CCI (>3)P
Age (years)54.49±10.6069.23±7.460
FEV1%pred78.22±7.7172.58±10.520
Extubation time (days)6.82±6.007.34±7.020.171
Anesthesia time (min)258.48±109.23246.58±90.540.058
Operation time (min)203.18±94.22192.35±88.170.053
Blood loss (mL)204.86±265.09191±229.230.368
Discharge (d)10.31±6.9411.11±7.850.067
Sex0.127
   Male517238
   Female401153
Smoking history0.857
   Yes352152
   No566239
Surgery0
   Wedge218126
   Segmentectomy2117
   Lobectomy601230
   Bilobectomy7818
Operative method0.001
   VATS615291
   VAMT20180
   Thoracotomy10220
Blood transfusion0.916
   Yes7230
   No846361
ASA classification0
   I/II841304
   III/IV7787
Pathology0
   Malignant631340
   Benign28751
Poor outcome0
   Yes3036
   No888355
30-day death0.338
   Yes54
   No913384
Complication0
   Yes160101
   No758290

CCI, Charlson comorbidity index; VATS, video-assisted thoracoscopic surgery; VAMT, video-assisted minithoracotomy; ASA, American Society of Anesthesiologists; FEV1%pred, predicted of forced expiratory volume in 1 s.

CCI, Charlson comorbidity index; VATS, video-assisted thoracoscopic surgery; VAMT, video-assisted minithoracotomy; ASA, American Society of Anesthesiologists; FEV1%pred, predicted of forced expiratory volume in 1 s.

Discussion

Comorbidity was associated with increased postoperative mortality and considered to be an important prognostic factor in patients operated for cancer (7). Battafarano et al. studied 451 patients who underwent surgical resection and founded that comorbidity had a significant impact on survival (8). Powell et al. studied 10,991 patients undergoing pulmonary resection and found that there was a significant correlation between CCI and death within 90 days after the operation (9). These comorbid conditions could affect the selection of treatment options. In this retrospective analysis of 1,309 patients, we confirmed a relationship between CCI and short-term outcomes. With the increase of CCI score, postoperative complications, the rate of transfer to ICU, and death within 90 days after operation also increased. However, there remains a problem in which CCI score cutoff was of guiding significance? Wang et al. suggested that Patients with CCI ≥2 and age ≥65 years had higher perioperative mortality and death from non-cancer causes after surgery compared to patients with CCI <2 (10). The presence of comorbid conditions (CCI >1), rather than age more than 65 years, was associated with poorer survival in a large randomized trial by Asmis et al. (11). The main finding of the present study was that CCI >3 was associated with a higher incidence of postoperative complications. Our cutoff point was higher than that of previous studies. The possible reason could be that they did not include age in the calculation of the CCI score. Age and comorbidity have been associated with overall and disease-specific outcomes in various cancers. A few reports have shown, however, that advanced age is not necessarily associated with higher morbidity (11,12). Koppie et al. believed that both age and comorbidity were associated with treatment selection and survival and should, therefore, be considered (13). Wang et al. demonstrated that advancing age was a much stronger negative predictor of treatment receipt among older veterans with lung cancer than comorbidity (14). Individualized decisions that go beyond age and include comorbidity were needed to better target lung cancer treatments to older patients who might reasonably benefit. In our calculation, the age of patients in CCI is assigned to an age group, each of which is considered to have a different risk. Our study showed that patients with CCI >3 had more poor outcomes (P<0.001), but the 30-day death rate was no significant difference (P=0.338). Similarly, Battafarano showed that there was no significant trend toward higher hospital mortality with greater comorbidity (P=0.055) (8). We considered that even patients with high CCI could perform surgery safely as long as appropriate patients were selected. In our study, the more lung tissue resected, the higher the incidence of postoperative complications. For patients with the same disease, patients with CCI ≤3 could tolerate more lung tissue resection. With the development of surgical techniques, VATS has been rapidly developed and widely applied in the world, involving almost all areas of general thoracic surgery. Compared with thoracotomy, VATS enabled a smaller incision without removing or stretching the ribs open, sparing respiratory muscles from injures and thus minimizing the loss of lung function. Patients would suffer less pain postoperatively and expectorate more easily, reducing the incidence of postoperative pulmonary infection and complications as well (15). Jeon et al. suggested that VATS lobectomy was associated with a lower incidence of pulmonary complications compared with lobectomy by thoracotomy in NSCLC patients with COPD (16). VATS lobectomy might be the preferred strategy for appropriately selected NSCLC patients with COPD. Garzon et al. believed that VATS pulmonary resection for cancer in patients with poor lung function could achieve an acceptable outcome (17). We found that the incidence of postoperative complications after thoracotomy was 1.7 times higher than that of VATS. VATS had fewer complications than other operations. Through 58 consecutive patients undergoing a VATS lobectomy for NSCLC, Nakanishi et al. demonstrated that a VATS lobectomy was a feasible and safe procedure for lung cancer in patients with a CCI score of two or more (18). In our study, the proportion of VATS used in CCI >3 group was more than that in CCI ≤3 group. For patients with CCI >3, surgeons preferred to use the most simple and quick operations. We recommended that it was very important for patients with CCI >3 to adopt the fastest way of operation and keep as much lung function as possible. With lung cancer being far more frequent in smokers and ex-smokers, these patients often have tobacco-related illnesses, mainly cardiovascular and respiratory (19). Unfortunately, in our study, smoking history was no significant difference between the complications group (P=0.075) and the CCI group (P=0.857). We inferred that postoperative complications and CCI were more closely related to smoking index than smoking history, and then we had no smoking index data. Smoking cessation should be strongly encouraged in patients who undergo pulmonary resections, regardless of CCI. For patients in CCI >3 group, the operation related time was shorter, hospitalization related time was longer, and the hospitalization cost was correspondingly increased. The surgeons were more rigorous in the perioperative management of such patients, hoping to reduce perioperative complications. In the research of Birim et al., the mean length of hospital stay was 14.4 days, ranging from 2 to 116. An increase of CCI score showed a slight increase in the length of hospital stay, although this was not significant (P=0.107) (4). ASA classification was used in the anesthesiology department to evaluate the physical condition and the surgical risk of patients (20). Marret et al. (21) and Limmer et al. (22) found that the ASA classification of III and IV correlated with poor outcomes in patients receiving pulmonary resection. The higher the CCI score, the higher the ASA classification (P<0.001). Whitmore et al. demonstrated that the CCI score and ASA grade were significantly correlated, with Spearman ρ of 0.458 (P<0.001). Increasing CCI score (P=0.0032) and ASA grade (P=0.0035) were associated with an increased likelihood of complications (23). Several limitations should be noted in this study. First, as a retrospective study, it was vulnerable to various sources of deviation that might not be identified and controlled. Second, this was a single institutional study with limited sample size and thus calls for more evidence from further prospective studies (including a larger series of patients). Future multicenter studies were needed to exploit possible predictive parameters that did not reach significance in our study, to provide better prognostic value for patients who have comorbidities.

Conclusions

CCI was associated with increased postoperative complications and considered to be an important prognostic factor in pulmonary resection patients. The main finding of the present study was that CCI >3 was associated with a poor short-term outcome. VATS pulmonary resection could be safely and effectively performed for patients with lung disease and comorbidity with satisfactory short-term outcomes. For patients with CCI >3, it was suggested that the experienced surgical team should perform pulmonary resection in the shortest time and keep the lung function as much as possible. Smoking cessation should be strongly encouraged in patients who undergo pulmonary resections. The CCI score and ASA grade were significantly correlated. The article’s supplementary files as
  23 in total

1.  Risk and protective factors for major complications after pneumonectomy for lung cancer.

Authors:  Emmanuel Marret; Farhat Miled; Bernard Bazelly; Sonia El Metaoua; Jacques de Montblanc; Christophe Quesnel; Jean-Pierre Fulgencio; Francis Bonnet
Journal:  Interact Cardiovasc Thorac Surg       Date:  2010-03-25

2.  Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer.

Authors:  Richard J Battafarano; Jay F Piccirillo; Bryan F Meyers; Han-Shui Hsu; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson
Journal:  J Thorac Cardiovasc Surg       Date:  2002-02       Impact factor: 5.209

3.  Video-assisted thoracoscopic lobectomy in non-small-cell lung cancer patients with chronic obstructive pulmonary disease is associated with lower pulmonary complications than open lobectomy: a propensity score-matched analysis.

Authors:  Jae Hyun Jeon; Chang Hyun Kang; Hye-Seon Kim; Yong Won Seong; In Kyu Park; Young Tae Kim; Joo Hyun Kim
Journal:  Eur J Cardiothorac Surg       Date:  2013-09-19       Impact factor: 4.191

4.  Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.

Authors:  Sunny Wang; Melisa L Wong; Nathan Hamilton; J Ben Davoren; Thierry M Jahan; Louise C Walter
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 5.  Does video-assisted thoracic surgery provide a safe alternative to conventional techniques in patients with limited pulmonary function who are otherwise suitable for lung resection?

Authors:  Jonathan Oparka; Tristan D Yan; Eilise Ryan; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-03-26

6.  Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.

Authors:  Timothy R Asmis; Keyue Ding; Lesley Seymour; Frances A Shepherd; Natasha B Leighl; Tim L Winton; Marlo Whitehead; Johanna N Spaans; Barbara C Graham; Glenwood D Goss
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

7.  Video-assisted thoracic surgery lobectomy for non-small cell lung cancer in patients with a Charlson comorbidity index score of two or more.

Authors:  Ryoichi Nakanishi; Toshihiro Yamashita; Soichi Oka
Journal:  J Thorac Oncol       Date:  2010-01       Impact factor: 15.609

8.  Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer.

Authors:  O Birim; A P W M Maat; A P Kappetein; J P van Meerbeeck; R A M Damhuis; A J J C Bogers
Journal:  Eur J Cardiothorac Surg       Date:  2003-01       Impact factor: 4.191

9.  Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer.

Authors:  Theresa M Koppie; Angel M Serio; Andrew J Vickers; Kinjal Vora; Guido Dalbagni; S Machele Donat; Harry W Herr; Bernard H Bochner
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

10.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

View more
  3 in total

1.  Evaluation of the Potential Risk of Mortality from SARS-CoV-2 Infection in Hospitalized Patients According to the Charlson Comorbidity Index.

Authors:  Jose Roberto Gutierrez-Camacho; Lorena Avila-Carrasco; Alberto Murillo-Ruíz-Esparza; Idalia Garza-Veloz; Roxana Araujo-Espino; Maria Calixta Martinez-Vazquez; Perla M Trejo-Ortiz; Iram Pablo Rodriguez-Sanchez; Iván Delgado-Enciso; Maria E Castañeda-López; Araceli Gamón-Madrid; Margarita L Martinez-Fierro
Journal:  Healthcare (Basel)       Date:  2022-02-12

2.  The Impact of the Age, Dyspnoea, and Airflow Obstruction (ADO) Index on the Medical Burden of Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Chin-Ling Li; Mei-Hsin Lin; Yuh-Chyn Tsai; Ching-Wan Tseng; Chia-Ling Chang; Lien-Shi Shen; Ho-Chang Kuo; Shih-Feng Liu
Journal:  J Clin Med       Date:  2022-03-29       Impact factor: 4.241

3.  Comparison of Major Clinical Outcomes between Accredited and Nonaccredited Hospitals for Inpatient Care of Acute Myocardial Infarction.

Authors:  Bo Yeon Lee; You Jin Chun; Yo Han Lee
Journal:  Int J Environ Res Public Health       Date:  2021-03-15       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.